BioTime receives NIH grant for retinal restoration program

The NIH awarded a grant of $743,345 to BioTime to advance its next-generation retinal restoration program, according to a press release.

The award, from the Small Business Innovation Research program at the NIH, is the second year of funding of a $1.6 million grant.

“This NIH grant program is incredibly competitive, so this award provides further validation of our advances in retinal restoration initiatives, in a continued effort to develop a robust pipeline of cell therapy products for ophthalmology,” Francois Binette, PhD, senior vice president and head of global development at BioTime, said in the release.

The retinal restoration program has successfully grown complete human 3-D retinal tissue derived from human pluripotent cells, the release said. The company is working toward developments to address advanced retinal diseases and injuries.

The NIH awarded a grant of $743,345 to BioTime to advance its next-generation retinal restoration program, according to a press release.

The award, from the Small Business Innovation Research program at the NIH, is the second year of funding of a $1.6 million grant.

“This NIH grant program is incredibly competitive, so this award provides further validation of our advances in retinal restoration initiatives, in a continued effort to develop a robust pipeline of cell therapy products for ophthalmology,” Francois Binette, PhD, senior vice president and head of global development at BioTime, said in the release.

The retinal restoration program has successfully grown complete human 3-D retinal tissue derived from human pluripotent cells, the release said. The company is working toward developments to address advanced retinal diseases and injuries.